References
- Pizzo P.A. Empiric therapy and prevention of infection in the immunocompromised host. Principles and practice of infectious diseases, 3rd ed, G.L. Mandell, R.G. Douglas, Jr., J.E. Bennett. Churchill Livingstone, New York 1990; 2303–2311
- Schimpff S.C., Young V.M., Greene W.H., Vermeulen G.D. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann. Int. Med. Jl. lian-llU. 1972
- Hellman S. Principles of radiation therapy. Cancer: Principles and practice of oncology, 4th ed, V.T. DeVita, Jr., S. Hellman, S.A. Rosenberg. JB Lippincott Company, Philadelphia 1989; 248–279
- Schimpff S.C. Infections in the compromised host. Principles and practice of infectious diseases, 3rd ed, G.L. Mandell, R.G. Douglas, Jr., J.E. Bennett. Churchill Livingstone, New York 1990; 2258–2265
- Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Qualitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann. Int. Med. 1966; 64: 328–340
- Hollingshead L.M., Goa K.L. Recombinant granulocyte colony-stimulating factor (rG-CSF): A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300–330
- Herrmann F., Schulz G., Wieser M., Kolbe K., Nicolay U., Noack M., Lindemann A. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am. J. Med. 1990; 88: 619–624
- Nemunaitis J., Rabinowe S.N., Singer J.W., Bierman P.J., Vose J.M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Eng. J. Med. 1991; 324: 1773–1778
- Gabrilove J.L., Jakubowski A., Scher H., Sternberg C., Wong G. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Eng. J. Med. 1988; 318: 1414–1422
- Crawford J., Ozer H., Stoller R., Johnson D., Lyman G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Eng. J. Med 1991; 325: 164–170
- Stewart A.K., Brandwein J.M., Stutcliffe S.B., Scott J.G., Keating A. Minibeam as salvage chemotherapy for refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 1991; 5: 111–115
- Chopra R., Linch D.C., McMillan A.K., Blair S., Patterson K.G. Mini-beam followed by BEAM and ABMT for very poor risk Hodgkin's Disease. Br. J. Haematol. 1992; 81: 197–202
- Gulati S.C., Bennett C.L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann. Int. Med. 1992; 116: 177–182
- Glaspy J.A., Bleecker G.C., Crawford J., Stoller R.G., Strauss M.J. Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony stimulating factor. Clin. Res. 1991; 39: 7A, (abstract)
- Lyman G.H., Lyman C.G., Sanderson R.A., Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J. Nat. Cancer Inst. 1993; 85: 488–493
- McMaster M.L., Greer J.P., Greco A., Johnson D.H., Wolff S.N., Hainsworth J.D. Effective treatment of small-non-cleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J. Clin. Oncol. 1991; 9: 941–946
- Frazio M.T., Glaspy J.A. The impact of granulocyte colony stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol. Nurs. Forum 1991; 18: 1411–1414